2401 ELLIOTT AVENUE, SEATTLE, WA
Investor Presentation
Appoints Biotech Veteran Joel Sendek as Chief Financial Officer
Appoints Maya Martinez-Davis to Board of Directors
Provides Recent Business Highlights and Reports 2Q 2025 Results
Q2
Q1
Amended Annual Report
FY 2024
Q3
FY 2023
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Specialized Disclosure Report
Post-Effective Amendment to Registration Statement
Free Writing Prospectus
Correspondence
Submission Upload